Back to Search Start Over

Design and validation of an oligonucleotide microarray for the detection of genomic rearrangements associated with common hereditary cancer syndromes.

Authors :
Mancini-DiNardo, Debora
Judkins, Thaddeus
Woolstenhulme, Nick
Burton, Collin
Schoenberger, Jeremy
Ryder, Matthew
Murray, Adam
Gutin, Natalia
Theisen, Aaron
Holladay, Jayson
Craft, Jonathan
Arnell, Christopher
Moyes, Kelsey
Roa, Benjamin
Source :
Journal of Experimental & Clinical Cancer Research (17569966); 2014, Vol. 33 Issue 1, p1-16, 16p
Publication Year :
2014

Abstract

Background Conventional Sanger sequencing reliably detects the majority of genetic mutations associated with hereditary cancers, such as single-base changes and small insertions or deletions. However, detection of genomic rearrangements, such as large deletions and duplications, requires special technologies. Microarray analysis has been successfully used to detect large rearrangements (LRs) in genetic disorders. Methods We designed and validated a high-density oligonucleotide microarray for the detection of gene-level genomic rearrangements associated with hereditary breast and ovarian cancer (HBOC), Lynch, and polyposis syndromes. The microarray consisted of probes corresponding to the exons and flanking introns of BRCA1 and BRCA2 (≈1,700) and Lynch syndrome/polyposis genes MLH1, MSH2, MSH6, APC, MUTYH, and EPCAM (≈ 2,200). We validated the microarray with 990 samples previously tested for LR status in BRCA1, BRCA2, MLH1, MSH2, MSH6, APC, MUTYH, or EPCAM. Microarray results were 100% concordant with previous results in the validation studies. Subsequently, clinical microarray analysis was performed on samples from patients with a high likelihood of HBOC mutations (13,124), Lynch syndrome mutations (18,498), and polyposis syndrome mutations (2,739) to determine the proportion of Lrs. Results Our results demonstrate that LRs constitute a substantial proportion of genetic mutations found in patients referred for hereditary cancer genetic testing. Conclusion The use of microarray comparative genomic hybridization (CGH) for the detection of LRs is well-suited as an adjunct technology for both single syndrome (by Sanger sequencing analysis)and extended gene panel testing by next generation sequencing analysis. Genetic testing strategies using microarray analysis will help identify additional patients carrying LRs, who are predisposed to various hereditary cancers. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17569966
Volume :
33
Issue :
1
Database :
Complementary Index
Journal :
Journal of Experimental & Clinical Cancer Research (17569966)
Publication Type :
Academic Journal
Accession number :
98703887
Full Text :
https://doi.org/10.1186/s13046-014-0074-9